Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR and colon cancer: a clinical view.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Jan 2008

de Castro-Carpeño J, Belda-Iniesta C, Casado Sáenz E, Hernández Agudo E, Feliu Batlle J, González Barón M

Abstract excerpt

Signalling pathways that emerge from EGFR activation are critical in colon cancer (CC) biology. Its targeting with specific drugs has opened a new window in the treatment of this disease. In this regard, monoclonal antibodies (mAb) have evidenced a high degree of efficiency opposed to the uselessness of tyrosine-kinase inhibitors. Cetuximab is the mAb that has evidenced most activity in CC. After its initial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colonic Neoplasms

Share to Gene Amplification

Share to Genes, ras

Share to In Situ Hybridization, Fluorescence

Share to Panitumumab

Source

Identifiers

PMID: 18208787
DOI: 10.1007/s12094-008-0147-3

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR and colon cancer: a clinical view.PMID 18208787Read ↗

[Molecular targets for colon cancer. VEGF, EGFR - and what else?].Semantic proximity Read ↗

Panitumumab in the treatment of colon cancer: A biomarker dilemma.Semantic proximity Read ↗

Targeting the epidermal growth factor receptor in metastatic colorectal cancer.Semantic proximity Read ↗

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.Semantic proximity Read ↗

Different treatment strategies and molecular features between right-sided and left-sided colon cancers.Semantic proximity Read ↗

Targeted therapy in advanced colorectal cancer: more data, more questions.Semantic proximity Read ↗

Impact of cetuximab in current treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Prognostic significance of EGFR and COX-2 expression in colorectal cancer and their association. A study in Greek population.Semantic proximity Read ↗

Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Cetuximab, its clinical use and future perspectives.Semantic proximity Read ↗

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read ↗

Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.